Kevin Pollack

This profile gathers the share dealings of Kevin Pollack across 4 companies, led by Pressure Biosciences Inc, Magnegas Corp and Opiant Pharmaceuticals, Inc. In total, 39 filings cover trades dated from 13 September 2016 to 27 March 2024.

No open-market sale appears; the market trades are 5 purchases worth €86k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 7 share grants.

A typical purchase (the median) is worth €9,404. Clusters matter here: 5 out of 5 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 28 March 2024 came the latest disclosure, a transaction for €430 in Pressure Biosciences Inc. The last insider purchase was made public on 1 April 2020, 2,396 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.